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Abstract
BACKGROUND: Raise of ovarian cancer mortality is caused by high ovarian cancer recurrence. This is related to 
many prognostic factors. Kirsten-rat sarcoma virus oncogene (KRAS) is a proto-oncogene that regulates proliferation, 
growth and cell motility. The controversy of some experts regarding KRAS mutations in the prognosis of ovarian 
cancer makes it interesting to analyze. 
AIM: The aim of this study is to clarify whether the clinicopathologic factors and KRAS gene mutation affect the 
recurrence of patients with ovarian cancer in Indonesia.
METHODS: The authors conducted a retrospective cohort study. Clinicopathological factors and prognoses were 
obtained for 205 patients who were histopathologically diagnosed with epithelial ovarian cancer or ovarian borderline 
malignant tumor, operated from June 2015 to January 2019 at Dr. M. Djamil General Hospital. We gathered 80 patients 
who were diagnosed with epithelial ovarian cancer since June 2015 until January 2019. These cases were analyzed after 
2-year follow-up or recurrence occurred. Survival rate was determined using the Kaplan–Meier method and examined by 
Log rank test. All analyses were performed using STATA ver. 12.0, with p < 0.05 considered to be significant.
RESULTS: Among KRAS mutation group, the 2-year disease free survival rate (2y-DFS) was 31.56% and 47.58% 
in non-mutation group with significant differences between mutation and non-mutation (p = 0.02). There was a 
significant difference between early stage ovarian cancer with non-mutation group and advanced stages ovarian 
cancer with mutation group (p = 0.00). Among combination staging with mutation group, the 2y-DFS was 85.79% in 
early stage ovarian cancer with non-mutation, 44.44% in early stage with mutation, 10.65% in advanced stage with 
non-mutation, and 20.00% in advanced stage with mutation.
CONCLUSION: The results suggest that staging and KRAS mutation are the most influence prognostic factors for 
epithelial ovarian cancer. There was a discrepancy of prognosis by staging and mutation between early stage with 
non-mutation and advanced stage with KRAS mutation.
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Introduction
Ovarian cancer has a high incidence and 
mortality rate in the world. Deaths due to ovarian cancer 
are caused by the recurrence of ovarian cancer. This is 
inseparable from various prognostic factors associated 
with recurrence, such as staging, grading and which is 
currently the center of attention by many experts that 
are gene mutation. One of the gene mutations that have 
been studied in cancer pathophysiology is the Kirsten-
rat sarcoma virus oncogene (KRAS) [1], [2]. Under 
normal conditions, KRAS is a proto-oncogene that is 
involved in the signaling pathway that regulates various 
important cellular functions such as proliferation, 
growth, and motility [3], [4].
There is controversy among some experts 
who analyze the ovarian cancer prognosis associated 
with KRAS mutation. One researcher declared that 
KRAS mutation can occur at an early stage of ovarian 
cancer and had a good prognosis, on the other hand, 
there were researchers who reported that the KRAS 
mutation was associated with high recurrence rate and 
poor prognosis [5], [6]. The aim of this study is to prove 
that staging, grading, and KRAS exon 2 mutations will 
influence recurrence in epithelial ovarian cancer.
Materials and Methods
Study design and research samples
The authors conducted a retrospective cohort 
study. Clinicopathological factors and prognoses were 
obtained for 205 patients who were histopathologically 
diagnosed with epithelial ovarian cancer or ovarian 
borderline malignant tumor, operated from June 2015 to 
January 2019 at Dr. M. Djamil General Hospital. Approval 
was obtained from the Ethics Boards of Andalas University 
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(approval No. 2072/KEP/FK/2020) and Dr. M. Djamil 
General Hospital (approval No. 86/KEPK/2020). Among 
the 205 patients, those with missing prognostic data were 
excluded, leaving 80 patients for analysis, including 40 
patients with mucinous ovarian cancer and 40 patients 
with non-mucinous ovarian cancer.
Data collection technique
Staging were classified based on FIGO 2014 
which were divided into early stage (stage IC2-IIA) and 
advanced stage (Stage IIB-IVB). Grading was classified 
based on Shimizu-Silverberg criteria. All slides were 
reviewed for grading by one pathologist. KRAS mutation 
was classified into mutation and non-mutation based on 
sequencing. Regarding the recurrence, patients were 
followed up to see whether there was a recurrence 
based on the presence or absence of complaints 
and ultrasound examination. Because of COVID-19 
pandemic, patients were followed up only by phone call.
Regarding the histological type, serous 
carcinoma + endometrial carcinoma + clear cell 
carcinoma was defined as the non-mucinous group, 
and mucinous carcinoma as the mucinous group for 
analysis because it is known that non-mucinous group 
cancer is often less frequent KRAS gene mutation, 
whereas mucinous group cancer is often more frequent 
KRAS gene mutation [5].
Data analysis
Clinicopathological factors and KRAS mutation 
were analyzed by χ2 test multivariate analysis by 
logistic regression. Survival rate was determined using 
the Kaplan–Meier method and examined by Log rank 
test. All analyses were performed using STATA ver. 
12.0 (StataCorp, 4905 Lakeway Drive College Station, 
Texas, USA), with p < 0.05 considered to be significant.
Results
Characteristic of the study subjects (Table 1).
Table 1: Characteristics of the study subjects
Characteristics f/% Median (Min-Max)
Age (years) 48 (24–80)
Observation period (months) 19.88
Stage
Stage I
Stage II
Stage IIIB
Stage IV
35 (43.75)
12 (15.00)
27 (33.75)
6 (7.50)
Grading
Low grade
High grade
33 (41.25)
47 (58.75)
Histological classification
Mucinous carcinoma 
Serous carcinoma
Clear cell carcinoma
Endometrioid carcinoma
40 (50.00)
25 (31.25)
10 (12.50)
5 (6.25)
Table 1 identified that the median age of 
the patients was 48 years (range: 24–80 years). The 
median observation period was 19.88 months. In the 
FIGO 2014 classification, 35 patients were classified 
as Stage I (29 as Stage IC2 and 6 as Stage IC3), 12 
as Stage II (4 as Stage IIA and 8 as Stage IIB), and 
27 as Stage IIIB, and 6 as Stage IV (4 as Stage IVA 
and 2 as Stage IVB). In the histological classification, 
40 cases were classified as mucinous carcinoma, 25 as 
serous carcinoma, ten as clear cell carcinoma, and five 
as endometrioid carcinoma. In two-tier grading system 
(Shimizu-Silverberg), 33 cases were classified as low 
grade and 47 as high grade.
Comparison of 2-year disease-free survival 
rates between non-mutation KRAS and mutation KRAS 
gene (Table 2).
Table 2: Comparison of 2-year disease-free survival rates 
between non-mutation KRAS and mutation KRAS gene
KRAS exon 2 n Median 
(months)
Survival rate (%) Cox-regression
12 months 24 months HR 95% CI p
Non-mutation 61 22.5 70.49 47.58 Ref - -
Mutation 19 13.9 57.89 31.56 2.086 1.14–3.79 0.01*
*Statistically significant, HR: Hazard ratio.
Table 2 shows that the 2-year disease-free 
survival rates in KRAS group were 47.58% in non-
mutation and 31.56% in mutation, with significant 
differences between two groups (Figure 1).
Figure 1: Kaplan–Meier comparison of 2-year disease-free survival 
rates between non-mutation KRAS and mutation KRAS gene
Comparison of 2-year disease-free survival 
rates between staging and mutation KRAS gene 
(Table 3).
Table 3: Comparison of 2-year disease-free survival rates 
between staging and mutation KRAS gene
Staging and 
KRAS gene
n Median 
(months)
Survival rate (%) Cox-regression
12 months 24 months HR 95% CI p
Early stage-non 
mutation
30 25,5 93,33 85,79 Ref - -
Early stage-
KRAS mutation
9 17,9 88,89 44,44 3,632 1,26–10,42 0,02
Advanced stage-
non mutation
31 11,9 48,39 10,65 7,116 3,25–15,53 0,00
Advanced stage - 
KRAS mutation
10 6,5 30,00 20,00 11,413 4,51–28,87 0,00
Table 3 known that the 2-year disease-free 
survival rates (2y-DFS) in non-mutation group were 
85.79% in early stage, and 10.65% in advanced stage. 
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The 2-year 2y-DFS in mutation group were 44.44% 
in early stage, and 20.00% in advanced stage with 
significant differences between early stage with non-
mutation and advanced stage with mutation (p = 0.00) 
(Figure 2).
Figure 2: Kaplan–Meier comparison of 2-year disease-free survival 
rates between staging and mutation KRAS gene
Discussion
In this study, we analyzed that clinicopathologic-
molecular prognostic factors (staging-grading-KRAS 
exon 2 mutation) are factors that cause an increase 
in ovarian cancer recurrence. Recurrence of ovarian 
cancer associated significantly with staging, grading, 
and KRAS exon 2 mutations.
There is a significant difference in the disease-
free survival of KRAS exon 2 mutations compared to 
non-mutation. Within 2 years, there was a decrease 
in survival by 68.44% in group with KRAS exon 2 
mutations. There was a significant difference in disease-
free survival in the advanced stage ovarian cancer 
group with the KRAS exon 2 mutations. There was a 
decrease in survival by 80% in the group advanced 
stage with KRAS exon 2 mutations in an interval of 2 
years.
Our data supported that the KRAS exon 2 
mutations are very important on disease-free survival. 
Previous study reported that the survival of ovarian 
cancer with KRAS mutations is shorter compared to 
without mutations (p < 0.05) [7]. Another study known, 
that cancer survival pulmonary mutations with KRAS 
mutations are shorter than those without mutations [8].
The clinical aspect in this study is the 
importance of the recommendation to ask patients 
to come up every 3 months regularly for 2 years 
postoperatively, especially in patients who have the 
KRAS exon 2 mutations. Previously, it is recommended 
to follow-up every 6 months after the first year, so 
with the results of this study are expected to follow-up 
patients remain 3 months for the 2nd year, not 6 months. 
This is useful to detect early if there is a recurrence in 
patients with advanced ovarian cancer with the KRAS 
exon 2 mutations.
The results of this study concluded that KRAS 
exon 2 mutations and prognostic factors significantly 
influenced recurrence in epithelial ovarian cancer. 
Since this is retrospective study that used 80 ovarian 
cancer tissues operated from June 2015 to January 
2019, grading was reviewed by one pathologist using 
two-tier system especially for mucinous carcinoma, 
sequencing by Sanger technique to assess exon 2 
mutations. Based on this sequencing, we found patients 
with multiple mutations.
In addition, recurrences were recorded by 
medical history of a patient and ultrasound examination. 
Therefore, DFS was analyzed for prognosis in this 
study. Despite these findings, this study has limitation 
that patients were followed up for recurrence only by 
phone call due to COVID-19 pandemic.
There was a significant difference in 2-year 
DFS among non-mutation and KRAS mutation group, 
suggesting that both groups clearly reflect the prognosis 
of ovarian cancer. Regarding combination staging and 
KRAS mutation, there were significant differences 
in 2y-DFS between early stage without mutation and 
early stage with mutation, advanced stage without 
mutation and advanced stage with mutation. In our 
study, prognosis in early stage without KRAS mutation 
differed significantly compared to early stage with 
mutation, but those in advanced stages without and 
with mutation were similar. The prognosis did not 
differ significantly between without mutation and with 
KRAS mutation in the advanced stage group, but was 
significantly different in the early stage group, and thus 
we believe that KRAS mutation is important prognostic 
factors, especially in early stage ovarian cancer [9].
The previous study found survival in the early 
stages (Stage I–II), there were differences in survival 
between groups with KRAS mutations compared 
to groups without mutations, but in the advanced 
stage group (Stage III–IV) there were no differences 
in survival between groups with KRAS mutations 
compared to groups without mutations (p > 0.05) [7]. 
Another research conducted the effect of staging and 
classification of type 1 and type 2 ovarian cancers on 
disease-free survival. Researcher reported that the 
highest survival was the type 1 ovarian cancer group 
with an early stage and the lowest survival was the 
type II ovarian group with advanced stage. This shows 
the role of staging greatly influences recurrence free 
survival [10].
In this study suggested the important in clinical 
aspects, especially in asking patients with advanced 
stage and KRAS mutation exon 2 for regular follow-up 
every 2 months in 1 year postoperatively. To detect a 
recurrence early so that it can be managed faster.
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Conclusion
The results of this study concluded that KRAS 
exon 2 mutations and clinicopathologic factors significantly 
influenced the recurrence in epithelial ovarian cancer.
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